Both companies delivered better-than-expected second-quarter results, but while Thermo Fisher (NYSE:TMO) raised guidance on broad-based demand improvement, Danaher’s (NYSE:DHR) recovery remains more uneven. Bull CaseThermo Fisher Scientific Inc.’s (NYSE:TMO) quarter suggests that the recovery in life sciences spending is becoming increasingly broad-based. Thermo Fisher Scientific Inc.’s (NYSE:TMO) Life Sciences Solutions segment reinforced the recovery narrative. Thermo Fisher Scientific Inc. (NYSE:TMO) also continued investing in product innovation through launches such as the Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers. Following management’s guidance increase, investors now expect Thermo Fisher Scientific (NYSE:TMO) to continue expanding margins while delivering stronger organic growth.